1. Clinical & Scientific Overview
Etizolam IP (TIP-MED-000399, Reference Code [11.5]-CMP129) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Short-to-Intermediate Acting Triazolobenzodiazepine (GABA-A Receptor Positive Allosteric Modulator; Anxiolytic).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Co-indexed per approved Author Decision DEC-06 (Option 6A; displaced HTML [11.18]). Short-acting thienodiazepine (Etilaam 0.25/0.5/1 mg).
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decision DEC-06 (Option 6A; displaced HTML [11.18]). Short-acting thienodiazepine (Etilaam 0.25/0.5/1 mg).
4. Therapeutic Indications & Evidence-Supported Uses
- Short-term symptomatic relief of acute generalised anxiety and panic attacks
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-06 (Option 6A; displaced HTML [11.18]). Short-acting thienodiazepine (Etilaam 0.25/0.5/1 mg).
Administration & Meal Timing: With or without food (swallow SR tablets whole). | At bedtime (or divided doses if prescribed for daytime panic).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [11.5].
Renal: Caution in severe CKD. Hepatic: Half-life doubles (from ~11 h to >20–30 h) in alcoholic liver disease / cirrhosis AND in elderly patients—avoid in severe hepatic impairment!
Renal: Caution in severe CKD. Hepatic: Half-life doubles (from ~11 h to >20–30 h) in alcoholic liver disease / cirrhosis AND in elderly patients—avoid in severe hepatic impairment!
Renal: Caution in severe CKD. Hepatic: Half-life doubles (from ~11 h to >20–30 h) in alcoholic liver disease / cirrhosis AND in elderly patients—avoid in severe hepatic impairment!
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in acute narrow-angle glaucoma, myasthenia gravis, severe respiratory insufficiency, obstructive sleep apnoea, severe hepatic failure, and co-administration with potent CYP3A4 inhibitors (ketoconazole, itraconazole).
Key Clinical Precautions: Renal: Caution in severe CKD. Hepatic: Half-life doubles (from ~11 h to >20–30 h) in alcoholic liver disease / cirrhosis AND in elderly patients—avoid in severe hepatic impairment!
8. Adverse Effects Profile
- Drowsiness, sedation, lightheadedness, impaired coordination/ataxia, anterograde amnesia (forgetfulness of events occurring hours after taking the pill), slurred speech, dry mouth, morning rebound anxiety as blood levels drop.
- Severe Physiological Dependence & Acute Withdrawal Syndrome (stopping alprazolam abruptly after ≥4 weeks causes severe rebound panic, insomnia, autonomic hyperactivity, delirium, psychosis, and life-threatening generalised tonic-clonic withdrawal seizures!), falls and hip fractures in the elderly, respiratory arrest when combined with opioids/alcohol.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Metabolised strictly by Hepatic CYP3A4: • Ketoconazole and Itraconazole are CONTRAINDICATED (increase Alprazolam AUC 3- to 4-fold!)
- • Clarithromycin, Erythromycin, Fluconazole, Diltiazem, Fluoxetine, Fluvoxamine, and Cimetidine double Alprazolam levels and cause profound sedation! • Opioids (Tramadol), Pregabalin, Zolpidem, and Alcohol: Fatal respiratory depression and falls
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.5].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Strongly discourage patients from using Alprax / Restyl every night for years as a 'sleeping pill for blood pressure'—explain that after 3 to 4 weeks, tolerance develops, memory weakens, and stopping suddenly becomes dangerous. 2. If an elderly patient has been taking Alprax 0.5 mg nightly for years, warn them NEVER to stop cold-turkey—any deprescribing must be an individualised, clinician-supervised process tailored to duration of use and withdrawal tolerance (typically an initial reduction of 5%–10% to 10%–25% every 1–2 to 4 weeks, with 25% representing the maximum initial step reduction appropriate only in selected shorter-term cases, and slowing further near the end of the taper).
- Meal & Clock Timing Instruction: With or without food (swallow SR tablets whole). (At bedtime (or divided doses if prescribed for daytime panic).)
- Missed Dose Protocol: If on PRN/bedtime use, skip if missed; if on chronic daily use, take as soon as remembered to prevent acute withdrawal, unless close to next dose.
- Geriatric Dispensing Pearl: Beers Criteria High-Risk Drug to Avoid in the Elderly: Causes severe anterograde amnesia, delirium, daytime ataxia, and hip fractures in CGHS seniors.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Scored Tablets: 0.25 mg, 0.5 mg, 1 mg; Sustained-Release (SR) Tablets: 0.5 mg, 1 mg, 1.5 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.25] Clozapine (Treatment-Resistant Schizophrenia — ANC Protocol) — Atypical Dibenzodiazepine Antipsychotic for Treatment-Resistant S
- [11.26] Lithium Carbonate (Mood Stabiliser — Narrow Therapeutic Index) — Monovalent Cation Mood Stabiliser (Inositol Monophosphatase & GSK
- [11.7]-CMP130 Nortriptyline Hydrochloride & Clomipramine Hydrochloride IP — Tertiary-Amine Tricyclic Antidepressant (TCA; Serotonin & Norepin
- [11.18]-C138 Desvenlafaxine Succinate — Serotonin–Noradrenaline Reuptake Inhibitors (SNRIs)
